Mobile

Randomized phase II study of sorafenib plus bicaluamide vs. placebo plus bicalutamide in castration-resistant asymptomatic or mildly symptomatic metastatic prostate cancer patients who had orchiectomy...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-006022-34

Randomized phase II study of sorafenib plus bicaluamide vs. placebo plus bicalutamide in castration-resistant asymptomatic or mildly symptomatic metastatic prostate cancer patients who had orchiectomy or are receiving a LHRH analogue

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this phase II study in castration-resistant metastatic prostate cancer patients who have had orciectomy or are receiving an LHRH analogue is to demonstrate a prolonged progression-fee survival (PFS) in the group treated with sorafenib and bicalutamide in comparison to those treated with placebo and bicalutamide.

Critère d'inclusion

  • metastatic prostate cancer

Liens